Skip to main content

Table 1 AIT recommendations

From: Allergy clinics in times of the SARS-CoV-2 pandemic: an integrated model

Recommendations in non COVID-19 individuals
Interrupting subcutaneous immunotherapy is not advised. Especially in potentially life-threatening allergies, such as venom allergy, SCIT should be regularly continued. The possibility of expanding injection intervals in the continuation phase should be checked and may be beneficial
Interrupting sublingual immunotherapy is not advised. Supply the patient with sufficient medication for a minimum of 14 days isolation
Sublingual immunotherapy can be taken at home. The intake of SLIT by the patient at home or any place is advantageous in avoiding contact with potentially infected persons
Both subcutaneous and sublingual immunotherapy can be continued in the current COVID-19 pandemics, in any asymptomatic patient without suspicion for SARS-CoV-2 infection and/or contact with SARS-CoV-2 positive individuals, in any patient with negative test result (RT-PCR) or in any patient after an adequate quarantine or with detection of serum IgG to SARS-CoV-2 without virus-specific IgM
Preparedness of your Allergy clinic is imperative to cope with COVID-19. Follow World Health Organization (WHO) guidelines and advice staff accordingly
These recommendations are conditional since there is paucity of data and they should be revised regularly with incoming new information on COVID-19
Recommendations in COVID-19 diagnosed cases or suspicion for SARS-CoV-2 infection
Interrupting subcutaneous immunotherapy is advised
Interrupting sublingual immunotherapy is advised
Both subcutaneous and sublingual immunotherapy should be discontinued in symptomatic patients with exposure or contact with SARS-CoV-2 positive individuals, or patients with positive test results (RT-PCR)